Czub Markus, Weingartl Hana, Czub Stefanie, He Runtao, Cao Jingxin
National Microbiology Laboratory, Canadian Science Centre for Human and Animal Health, 1015 Arlington Street, Winnipeg, Manitoba, Canada R3E 3R2.
Vaccine. 2005 Mar 18;23(17-18):2273-9. doi: 10.1016/j.vaccine.2005.01.033.
Severe acute respiratory syndrome (SARS) caused by a newly identified coronavirus (SARS-CoV) remains a threat to cause epidemics as evidenced by recent sporadic cases in China. In this communication, we evaluated the efficacy and safety of two SARS vaccine candidates based on the recombinant modified vaccinia Ankara (MVA) expressing SARS-CoV spike or nucleocapsid proteins in ferrets. No clinical signs were observed in all the ferrets challenged with SARS-CoV. On the other hand, vaccination did not prevent SARS-CoV infection in ferrets. In contrast, immunized ferrets (particularly those immunized with rMVA-spike) exhibited significantly stronger inflammatory responses and focal necrosis in liver tissue after SARS-CoV challenge than control animals. Thus, our data suggest that enhanced hepatitis is linked to vaccination with rMVA expressing SARS-CoV antigens.
一种新发现的冠状病毒（SARS-CoV）引起的严重急性呼吸综合征（SARS）仍然是引发疫情的威胁，中国近期的散发病例就证明了这一点。在本通讯中，我们评估了两种基于表达SARS-CoV刺突蛋白或核衣壳蛋白的重组改良安卡拉痘苗病毒（MVA）的SARS候选疫苗在雪貂中的有效性和安全性。在用SARS-CoV攻击的所有雪貂中均未观察到临床症状。另一方面，疫苗接种并未预防雪貂感染SARS-CoV。相比之下，免疫后的雪貂（特别是用rMVA-刺突蛋白免疫的雪貂）在受到SARS-CoV攻击后，肝脏组织中的炎症反应和局灶性坏死明显强于对照动物。因此，我们的数据表明，增强型肝炎与接种表达SARS-CoV抗原的rMVA有关。
Zotero 插件
